文献速递肿瘤 PET/CT放射性药物与辐射防护

PET/MRI与PET/CT在全身分期中的比较:1003例单中心观察性研究

PET/MRI Versus PET/CT for Whole-Body Staging: Results from a Single-Center Observational Study on 1,003 Sequential Examinations.
PubMed 文献 · J Nucl Med · 2019-12-05

该单中心观察性研究纳入1003例肿瘤全身检查,比较PET/MRI与PET/CT在病灶检测、分类及辐射剂量上的差异。PET/MRI在26.3%检查中提供额外信息,5.3%检出额外恶性病灶,2.9%改变TNM分期,且平均有效剂量3.6 mSv显著低于PET/CT的17.6 mSv。

要点

  • PET/MRI在26.3%检查中提供额外信息,5.3%检出额外恶性病灶。
  • PET/MRI使2.9%检查的TNM分期发生改变。
  • PET/MRI平均有效剂量3.6 mSv,较PET/CT的17.6 mSv降低79.6%。

核心结论

  • PET/MRI可实现与PET/CT相当的分期,并在部分肿瘤中提高病灶可检测性。
  • 年轻患者可能从PET/MRI较低的辐射暴露中获益。

研究设计与样本

  • 单中心观察性研究,纳入1003例肿瘤全身检查(918例患者,平均年龄57.8±14.4岁)。
  • 患者接受PET/CT后行PET/MRI(示踪剂给药后149.8±49.7分钟),由放射科与核医学科医师共识判读。

主要发现

  • PET/MRI在26.3%(264/1003)检查中报告额外信息(P<0.001)。
  • PET/MRI检出额外恶性病灶占5.3%(53/1003),导致2.9%(29/1003)TNM分期改变。
  • PET/MRI对11.1%(111/1003)PET/CT不确定病灶可明确分类。
  • PET/MRI漏诊恶性病灶占1.2%(12/1003),导致0.5%(5/1003)TNM分期改变。
  • PET/CT检出病灶在PET/MRI不可见者占2.9%(29/1003)。

关键数值与推荐

  • 全身PET/CT估计平均有效剂量为17.6±8.7 mSv。
  • 全身PET/MRI估计平均有效剂量为3.6±1.4 mSv。
  • PET/MRI相较PET/CT潜在剂量降低79.6%(P<0.001)。

临床怎么用

  • 对需额外MRI评估的肿瘤患者,PET/MRI可能实现局部与全身一步式分期。
  • 年轻肿瘤患者可优先考虑PET/MRI以降低辐射暴露。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Our purpose was to investigate differences between PET/MRI and PET/CT in lesion detection and classification in oncologic whole-body examinations and to investigate radiation exposure differences between the 2 modalities. Methods: In this observational single-center study, 1,003 oncologic examinations (918 patients; mean age, 57.8 ± 14.4 y) were included. Patients underwent PET/CT and subsequent PET/MRI (149.8 ± 49.7 min after tracer administration). Examinations were reviewed by radiologists and nuclear medicine physicians in consensus. Additional findings, characterization of indeterminate findings on PET/CT, and missed findings on PET/MRI, including their clinical relevance and effective dose of both modalities, were investigated. The McNemar test was used to compare lesion detection between the 2 hybrid imaging modalities (P < 0.001, indicating statistical significance). Results: Additional information on PET/MRI was reported for 26.3% (264/1,003) of examinations, compared with PET/CT (P < 0.001). Of these, additional malignant findings were detected in 5.3% (53/1,003), leading to a change in TNM staging in 2.9% (29/1,003) due to PET/MRI. Definite lesion classification of indeterminate PET/CT findings was possible in 11.1% (111/1,003) with PET/MRI. In 2.9% (29/1,003), lesions detected on PET/CT were not visible on PET/MRI. Malignant lesions were missed in 1.2% (12/1,003) on PET/MRI, leading to a change in TNM staging in 0.5% (5/1,003). The estimated mean effective dose for whole-body PET/CT amounted to 17.6 ± 8.7 mSv, in comparison to 3.6 ± 1.4 mSv for PET/MRI, resulting in a potential dose reduction of 79.6% (P < 0.001). Conclusion: PET/MRI facilitates staging comparable to that of PET/CT and improves lesion detectability in selected cancers, potentially helping to promote fast, efficient local and whole-body staging in 1 step, when additional MRI is recommended. Furthermore, younger patients may benefit from the reduced radiation exposure of PET/MRI.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Martin O, Schaarschmidt BM, Kirchner J, et al. PET/MRI Versus PET/CT for Whole-Body Staging: Results from a Single-Center Observational Study on 1,003 Sequential Examinations. J Nucl Med. 2019. PMID: 31806777. doi:10.2967/jnumed.119.233940

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。